Overview & Definition
Chimeric Antigen Receptor T-Cell (CAR-T) Therapy is a groundbreaking cellular immunotherapy. A patient's own immune T cells are harvested via apheresis, genetically modified in a certified laboratory with a synthetic receptor (CAR) to recognize tumor surface antigens (CD19 or BCMA), expanded into millions of anti-cancer effector cells, and reinfused into the patient.
Targeted Antigen Targets & Products
- CD19-Directed CAR-T Therapies – designed to target CD19 surface markers on B-cell malignancies (e.g., Tisagenlecleucel, Axicabtagene ciloleucel, Brexucabtagene autoleucel, Lisocabtagene maraleucel).
- BCMA-Directed CAR-T Therapies – engineered against B-Cell Maturation Antigen expressed on malignant plasma cells (e.g., Idecabtagene vicleucel, Ciltacabtagene autoleucel).
Clinical Indications & Eligibility
- Relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in pediatric and young adult patients
- Relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) after ≥2 prior lines of systemic therapy
- Relapsed or refractory Mantle Cell Lymphoma & Follicular Lymphoma
- Triple-class exposed relapsed/refractory Multiple Myeloma
The CAR-T Treatment Journey
- 1. 🩸 Patient Apheresis (T-Cell Collection) – white blood cells are collected in an outpatient apheresis suite.
- 2. 🧬 Genetic Modification & Expansion – T cells are transduced with a viral vector encoding the CAR gene and cultured.
- 3. 💊 Lymphodepleting Conditioning – 3 days of low-dose chemotherapy (Fludarabine + Cyclophosphamide) to prepare the bone marrow niche.
- 4. 💉 Single IV CAR-T Cell Infusion – reinfusion of the engineered living cell product.
- 5. 🏥 Inpatient Monitoring – strict observation for Cytokine Release Syndrome (CRS) and immune neurotoxicity (ICANS).
Diagnostic Evaluation
Comprehensive baseline medical clearance is mandatory before CAR-T cell apheresis:
- 🔍 Flow Cytometry – verifying positive target antigen expression (CD19 / BCMA) on leukemic blasts or lymphoma cells.
- 🔍 PET-CT Staging Scan – assessing baseline tumor burden.
- 🔍 Cardiac & Pulmonary Evaluation – Echocardiogram (LVEF ≥45%) and Pulmonary Function Tests (PFTs).
- 🔍 Central Nervous System Screening – brain MRI and CSF analysis to rule out active CNS leukemia.
Side Effects & Clinical Management
- 💊 Cytokine Release Syndrome (CRS) – systemic inflammatory response (fever, hypotension, hypoxia) treated promptly with Tocilizumab (IL-6 receptor antagonist) and corticosteroids.
- 💊 ICANS (Immune Effector Cell-Associated Neurotoxicity) – temporary confusion, handwriting changes, or dysphasia managed with intravenous corticosteroids.
- 💊 B-cell Aplasia & Hypogammaglobulinemia – long-term depletion of normal B cells managed with periodic IVIG (immunoglobulin) replacement.
Frequently Asked Questions
CAR-T therapy is specifically indicated for patients with relapsed or refractory B-cell leukemias, aggressive lymphomas, or multiple myeloma who have failed conventional chemotherapy lines. Eligibility depends on tumor antigen expression, overall organ fitness, and clinical evaluation by a specialized hemato-oncologist.
From initial T-cell collection (apheresis) through laboratory cell manufacturing and final reinfusion, the turnaround time typically ranges from 3 to 4 weeks. Following infusion, patients are monitored closely for 2 to 4 weeks in specialized isolation rooms.